By Dr Liz Dallimore, Neuroscientist, Nedlands
Acute stroke remains a leading cause of death and disability worldwide, where rapid intervention can mean the difference between recovery and permanent brain damage.
While thrombolysis and thrombectomy remain the foundation of ischaemic stroke treatment, a West Australian-developed neuroprotective drug may soon offer clinicians a new tool to preserve brain tissue in the crucial early hours as well as after treatment.
The current acute stroke workflow in emergency departments prioritises rapid recognition and imaging, with non-contrast CT and CT angiography used to assess eligibility for reperfusion therapies....
Acute stroke remains a leading cause of death and disability worldwide, where rapid intervention can mean the difference between recovery and permanent brain damage.
While thrombolysis and thrombectomy remain the foundation of ischaemic stroke treatment, a West Australian-developed neuroprotective drug may soon offer clinicians a new tool to preserve brain tissue in the crucial early hours as well as after treatment.
The current acute stroke workflow in emergency departments prioritises rapid recognition and imaging, with non-contrast CT and CT angiography used to assess eligibility for reperfusion therapies....
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.